交易 Blueprint Medicines Corporation - BPMC CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
交易條件
价差 | 0.28 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Blueprint Medicines Corp ESG Risk Ratings
High Medium Low Negligible
“B”分數表示相對 ESG 表現良好,公開報告重要 ESG 數據的透明度高於平均水平。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Apr 17, 2024 | 88.26 | 3.30 | 3.88% | 84.96 | 89.43 | 84.56 |
Apr 16, 2024 | 85.39 | 1.37 | 1.63% | 84.02 | 87.85 | 83.82 |
Apr 15, 2024 | 84.53 | -1.20 | -1.40% | 85.73 | 87.61 | 84.05 |
Apr 12, 2024 | 86.78 | -5.15 | -5.60% | 91.93 | 92.53 | 86.69 |
Apr 11, 2024 | 92.12 | 1.98 | 2.20% | 90.14 | 92.49 | 89.95 |
Apr 10, 2024 | 89.88 | 3.92 | 4.56% | 85.96 | 90.41 | 81.99 |
Apr 9, 2024 | 92.06 | 0.21 | 0.23% | 91.85 | 93.69 | 90.15 |
Apr 8, 2024 | 91.47 | 2.23 | 2.50% | 89.24 | 92.33 | 89.24 |
Apr 5, 2024 | 91.45 | 2.66 | 3.00% | 88.79 | 91.54 | 87.52 |
Apr 4, 2024 | 90.59 | 0.14 | 0.15% | 90.45 | 92.84 | 90.21 |
Apr 3, 2024 | 88.07 | -1.65 | -1.84% | 89.72 | 93.17 | 88.07 |
Apr 2, 2024 | 91.41 | -1.65 | -1.77% | 93.06 | 93.61 | 89.98 |
Apr 1, 2024 | 96.33 | 3.71 | 4.01% | 92.62 | 96.93 | 92.62 |
Mar 28, 2024 | 94.67 | 0.29 | 0.31% | 94.38 | 95.66 | 90.71 |
Mar 27, 2024 | 94.19 | 5.14 | 5.77% | 89.05 | 94.75 | 88.71 |
Mar 26, 2024 | 89.50 | 1.36 | 1.54% | 88.14 | 92.08 | 87.94 |
Mar 25, 2024 | 88.02 | 1.09 | 1.25% | 86.93 | 89.38 | 86.83 |
Mar 22, 2024 | 86.92 | -3.36 | -3.72% | 90.28 | 90.28 | 86.69 |
Mar 21, 2024 | 89.78 | 1.59 | 1.80% | 88.19 | 91.26 | 88.19 |
Mar 20, 2024 | 88.12 | 2.18 | 2.54% | 85.94 | 89.25 | 84.27 |
Blueprint Medicines Corporation Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Thursday, April 25, 2024 | ||
时间(协调世界时) (UTC) 14:00 | 国家 US
| 事件 Blueprint Medicines Corp To Discuss Emerging Opportunities for Mast Cell-Targeted Therapeutics Call Blueprint Medicines Corp To Discuss Emerging Opportunities for Mast Cell-Targeted Therapeutics CallForecast(预报) -上一页 - |
Thursday, May 2, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q1 2024 Blueprint Medicines Corp Earnings Release Q1 2024 Blueprint Medicines Corp Earnings ReleaseForecast(预报) -上一页 - |
Thursday, June 20, 2024 | ||
时间(协调世界时) (UTC) 19:30 | 国家 US
| 事件 Blueprint Medicines Corp Annual Shareholders Meeting Blueprint Medicines Corp Annual Shareholders MeetingForecast(预报) -上一页 - |
Wednesday, July 31, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q2 2024 Blueprint Medicines Corp Earnings Release Q2 2024 Blueprint Medicines Corp Earnings ReleaseForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 204.036 | 180.08 | 793.735 | 66.512 | 44.521 |
收入 | 204.036 | 180.08 | 793.735 | 66.512 | 44.521 |
總營業費用 | 741.554 | 822.061 | 485.028 | 427.838 | 291.549 |
銷售/一般/行政費用,總計 | 237.374 | 195.293 | 157.743 | 96.388 | 47.928 |
研究與開發 | 477.419 | 601.033 | 326.86 | 331.45 | 243.621 |
營業收入 | -537.518 | -641.981 | 308.707 | -361.326 | -247.028 |
利息收入(費用),非經營淨值 | -16.767 | 2.386 | 6.599 | 13.732 | -0.073 |
其他,淨值 | 2.004 | -1.489 | -0.366 | -0.1 | 10.459 |
稅前淨收入 | -552.281 | -641.084 | 314.94 | -347.694 | -236.642 |
稅後淨收入 | -557.517 | -644.085 | 313.882 | -347.694 | -236.642 |
未計算非常項目前的淨收益 | -557.517 | -644.085 | 313.882 | -347.694 | -236.642 |
淨收入 | -557.517 | -644.085 | 313.882 | -347.694 | -236.642 |
Total Adjustments to Net Income | 0 | ||||
普通股股東可獲收益 (不含非經常性項目) | -557.517 | -644.085 | 313.882 | -347.694 | -236.642 |
普通股股東可獲收益 (含非經常性項目) | -557.517 | -644.085 | 313.882 | -347.694 | -236.642 |
攤薄淨收入 | -557.517 | -644.085 | 313.882 | -347.694 | -236.642 |
攤薄後加權平均股 | 59.642 | 58.518 | 56.168 | 47.829 | 43.867 |
扣除特別項目的每股攤薄盈利 | -9.34772 | -11.0066 | 5.58827 | -7.26952 | -5.39453 |
每股正常攤薄盈利 | -9.34772 | -11.0066 | 5.58827 | -7.26952 | -5.39453 |
收入成本,共計 | 17.813 | 17.934 | 0.425 | ||
毛利 | 186.223 | 162.146 | 793.31 | ||
Other Operating Expenses, Total | 8.948 | 7.801 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
總收入 | 56.566 | 57.57 | 63.287 | 38.781 | 65.977 |
收入 | 56.566 | 57.57 | 63.287 | 38.781 | 65.977 |
收入成本,共計 | 2.782 | 2.323 | 3.175 | 4.848 | 3 |
毛利 | 53.784 | 55.247 | 60.112 | 33.933 | 62.977 |
總營業費用 | 185.546 | 185.551 | 187.494 | 188.58 | 190.254 |
銷售/一般/行政費用,總計 | 70.741 | 71.931 | 70.95 | 64.02 | 57.608 |
研究與開發 | 110.252 | 110.063 | 112.073 | 117.84 | 127.981 |
營業收入 | -128.98 | -127.981 | -124.207 | -149.799 | -124.277 |
利息收入(費用),非經營淨值 | -3.808 | -3.996 | -5.819 | -9.24 | -8.396 |
其他,淨值 | -0.728 | -0.626 | 0.986 | 1.429 | 0.396 |
稅前淨收入 | -133.516 | -132.603 | -129.04 | -157.61 | -132.277 |
稅後淨收入 | -133.713 | -132.793 | -129.56 | -158.646 | -133.163 |
未計算非常項目前的淨收益 | -133.713 | -132.793 | -129.56 | -158.646 | -133.163 |
淨收入 | -133.713 | -132.793 | -129.56 | -158.646 | -133.163 |
普通股股東可獲收益 (不含非經常性項目) | -133.713 | -132.793 | -129.56 | -158.646 | -133.163 |
普通股股東可獲收益 (含非經常性項目) | -133.713 | -132.793 | -129.56 | -158.646 | -133.163 |
攤薄淨收入 | -133.713 | -132.793 | -129.56 | -158.646 | -133.163 |
攤薄後加權平均股 | 60.688 | 60.516 | 60.126 | 59.876 | 59.758 |
扣除特別項目的每股攤薄盈利 | -2.20329 | -2.19435 | -2.15481 | -2.64958 | -2.22837 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -2.20329 | -2.19435 | -2.15481 | -2.64958 | -2.22837 |
Other Operating Expenses, Total | 1.771 | 1.234 | 1.296 | 1.872 | 1.665 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 1046.65 | 554.025 | 927.759 | 516.786 | 499.787 |
現金和短期投資 | 944.992 | 477.114 | 871.849 | 483.554 | 494.012 |
現金等價物 | 119.709 | 209.948 | 684.636 | 113.938 | 68.064 |
短期投資 | 825.283 | 267.166 | 187.213 | 369.616 | 425.948 |
應收賬款總額,淨額 | 36.938 | 37.03 | 25.309 | 23.412 | 0.215 |
應收賬款 - 貿易,淨額 | 36.938 | 37.03 | 25.309 | 23.412 | 0.215 |
預付的費用 | 35.024 | 18.064 | 22.02 | 9.82 | 5.56 |
總資産 | 1349.9 | 1252.22 | 1718.39 | 707.694 | 540.124 |
物業/廠房/設備,總計 - 淨額 | 115.198 | 120.862 | 101.668 | 111.114 | 29.627 |
物業/廠房/設備,總計 - 總額 | 146.48 | 146.28 | 121.399 | 124.798 | 38.282 |
累計折舊,總計 | -31.282 | -25.418 | -19.731 | -13.684 | -8.655 |
長期投資 | 133.48 | 557.529 | 677.873 | 64.406 | 0 |
其他長期資産,總計 | 54.573 | 19.809 | 11.093 | 15.388 | 10.71 |
流動負債總額 | 183.234 | 149.765 | 130.802 | 106.482 | 60.323 |
應付賬款 | 2.729 | 8.333 | 4.37 | 4.793 | 3.298 |
預提費用 | 141.702 | 129.922 | 113.873 | 95.529 | 51.711 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 16.851 | ||||
其他流動負債,總計 | 21.952 | 11.51 | 12.559 | 6.16 | 5.314 |
負債總額 | 835.225 | 281.49 | 248.305 | 243.335 | 121.115 |
長期債務總額 | 122.232 | 0 | 0 | 0 | 0 |
長期債務 | 122.232 | ||||
其他負債,總計 | 529.759 | 131.725 | 117.503 | 136.853 | 60.792 |
總權益 | 514.677 | 970.735 | 1470.09 | 464.359 | 419.009 |
普通股 | 0.06 | 0.059 | 0.058 | 0.049 | 0.044 |
額外實收資本 | 2358.02 | 2250.25 | 2106.6 | 1412.08 | 1016.69 |
留存收益(累計赤字) | -1832.96 | -1275.44 | -631.356 | -945.238 | -597.545 |
其他權益,總計 | -10.443 | -4.133 | -5.214 | -2.535 | -0.18 |
總負債和股東權益 | 1349.9 | 1252.22 | 1718.39 | 707.694 | 540.124 |
已發行普通股總數 | 59.9589 | 59.1411 | 57.7935 | 49.2722 | 44.037 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
總庫存 | 29.697 | 21.817 | 8.581 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 808.172 | 811.335 | 900.344 | 1046.65 | 1227.67 |
現金和短期投資 | 712.984 | 722.634 | 822.161 | 944.992 | 1136.96 |
現金等價物 | 55.972 | 75.527 | 169.724 | 119.709 | 291.43 |
短期投資 | 657.012 | 647.107 | 652.437 | 825.283 | 845.535 |
應收賬款總額,淨額 | 41.254 | 38.267 | 31.303 | 36.938 | 21.915 |
應收賬款 - 貿易,淨額 | 41.254 | 38.267 | 31.303 | 36.938 | 21.915 |
總庫存 | 16.457 | 17.016 | 17.521 | 29.697 | 35.253 |
預付的費用 | 37.477 | 33.418 | 29.359 | 35.024 | 33.532 |
總資産 | 1105.3 | 1106.44 | 1220.37 | 1349.9 | 1458.39 |
物業/廠房/設備,總計 - 淨額 | 115.84 | 114.486 | 113.409 | 115.198 | 117.371 |
物業/廠房/設備,總計 - 總額 | 146.48 | ||||
累計折舊,總計 | -31.282 | ||||
長期投資 | 114.242 | 113.932 | 139.15 | 133.48 | 55.675 |
其他長期資産,總計 | 67.045 | 66.692 | 67.467 | 54.573 | 57.681 |
流動負債總額 | 197.384 | 169.028 | 172.684 | 183.234 | 175.51 |
應付賬款 | 6.963 | 6.979 | 10.563 | 2.729 | 4.233 |
預提費用 | 122.053 | 112.454 | 119.622 | 141.702 | 130.879 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 38.147 | 31.738 | 25.117 | 21.952 | 25.108 |
負債總額 | 902.688 | 795.315 | 806.072 | 835.225 | 818.085 |
長期債務總額 | 208.157 | 122.146 | 122.13 | 122.232 | 123.06 |
其他負債,總計 | 497.147 | 504.141 | 511.258 | 529.759 | 519.515 |
總權益 | 202.611 | 311.13 | 414.298 | 514.677 | 640.307 |
普通股 | 0.061 | 0.061 | 0.06 | 0.06 | 0.06 |
額外實收資本 | 2434.26 | 2410.6 | 2381.36 | 2358.02 | 2329.39 |
留存收益(累計赤字) | -2229.02 | -2095.31 | -1962.52 | -1832.96 | -1674.31 |
其他權益,總計 | -2.683 | -4.221 | -4.602 | -10.443 | -14.826 |
總負債和股東權益 | 1105.3 | 1106.44 | 1220.37 | 1349.9 | 1458.39 |
已發行普通股總數 | 60.7407 | 60.6383 | 60.4163 | 59.9589 | 59.8085 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 30.221 | 17.857 | 17.382 | 16.851 | 15.29 |
長期債務 | 208.157 | 122.146 | 122.13 | 122.232 | 123.06 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -557.517 | -644.085 | 313.882 | -347.694 | -236.642 |
经营活动产生的现金 | -502.277 | -298.653 | 387.035 | -278.015 | -175.009 |
经营活动产生的现金 | 11.735 | 6.479 | 6.559 | 5.259 | 4.246 |
非现金物品 | 97.274 | 362.633 | 82.212 | 54.695 | 26.147 |
已付现金利息 | 9.814 | 0 | 0.005 | 0.267 | |
营运资金的变化 | -53.769 | -23.68 | -15.618 | 9.725 | 31.24 |
投资活动产生的现金 | -149.541 | -225.86 | -434.249 | -16.466 | -161.088 |
资本支出 | -8.919 | -3.089 | -3.159 | -14.013 | -12.677 |
其他投资现金流量项目,总计 | -140.622 | -222.771 | -431.09 | -2.453 | -148.411 |
融资活动产生的现金 | 561.81 | 50.716 | 617.759 | 340.638 | 4.454 |
融资现金流项目 | 415.828 | 0 | 0 | -0.4 | -0.281 |
股票的发行(报废),净额 | 8.196 | 50.716 | 617.759 | 341.038 | 6.425 |
债务的发行(退还),净额 | 137.786 | 0 | 0 | -1.69 | |
现金净变化 | -90.215 | -474.685 | 570.2 | 46.175 | -331.643 |
Cash Taxes Paid | 6.505 | 0.694 | 0.778 | 0.185 | |
外汇效应 | -0.207 | -0.888 | -0.345 | 0.018 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -129.56 | -557.517 | -398.871 | -265.709 | -105.999 |
Cash From Operating Activities | -122.961 | -502.277 | -380.872 | -250.982 | -132.726 |
Cash From Operating Activities | 3.684 | 11.735 | 4.719 | 3.098 | 1.628 |
Non-Cash Items | 29.336 | 97.274 | 60.743 | 53.403 | 26.249 |
Cash Taxes Paid | 0.311 | 6.505 | 4.018 | 0.771 | 0.169 |
Changes in Working Capital | -26.421 | -53.769 | -47.463 | -41.774 | -54.604 |
Cash From Investing Activities | 172.791 | -149.541 | -96.258 | 35.977 | -41.09 |
Capital Expenditures | -2.584 | -8.919 | -7.438 | -3.709 | -1.153 |
Other Investing Cash Flow Items, Total | 175.375 | -140.622 | -88.82 | 39.686 | -39.937 |
Cash From Financing Activities | 0 | 561.81 | 559.319 | 178.762 | 1.264 |
Issuance (Retirement) of Stock, Net | 0 | 8.196 | 5.686 | 3.762 | 1.264 |
Foreign Exchange Effects | 0.197 | -0.207 | -0.685 | -0.306 | -0.197 |
Net Change in Cash | 50.027 | -90.215 | 81.504 | -36.549 | -172.749 |
Financing Cash Flow Items | 415.828 | 415.836 | 175 | ||
Cash Interest Paid | 7.084 | 9.814 | 2.956 | ||
Issuance (Retirement) of Debt, Net | 137.786 | 137.797 |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Blueprint Medicines Corporation Company profile
关于 Blueprint Medicines Corporation
蓝图药品公司是一家全球精准治疗公司,正在为癌症和血液病患者发明药物。 公司向美国和欧洲的患者提供其批准的药物,包括AYVAKIT/AYVAKYT(阿瓦普利提尼)和GAVRETO(普拉西替尼),并在全球范围内推进系统性肥大症(SM)、肺癌和其他基因组癌症以及癌症免疫疗法的多个项目。 其管线还包括BLU-263(KIT)、AYVAKIT(阿瓦普利尼)(PDGFRA)、BLU-701(EGFR)、BLU-945(EGFR)、BLU-451(EGFR第20外显子插入)、BLU-222(CDK2)和BLU-852(MAP4K1)。 该公司正在开发和商业化用于治疗晚期SM的阿瓦普利尼,以及开发用于治疗非晚期SM的阿瓦普利尼。 公司正在开发BLU-263,一种研究性的、口服的KIT抑制剂,用于治疗非晚期SM和其他肥大细胞疾病。
Industry: | Biotechnology & Medical Research (NEC) |
45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球610,000万多名交易者的一份子,选择利用Capital.com进行交易吧。